BE1000253A3 - Preparation pharmaceutique stable contenant un facteur de stimulation des colonies de granulocytes et procede pour la produire. - Google Patents

Preparation pharmaceutique stable contenant un facteur de stimulation des colonies de granulocytes et procede pour la produire. Download PDF

Info

Publication number
BE1000253A3
BE1000253A3 BE8700787A BE8700787A BE1000253A3 BE 1000253 A3 BE1000253 A3 BE 1000253A3 BE 8700787 A BE8700787 A BE 8700787A BE 8700787 A BE8700787 A BE 8700787A BE 1000253 A3 BE1000253 A3 BE 1000253A3
Authority
BE
Belgium
Prior art keywords
sep
factor
pharmaceutical preparation
acid
preparation containing
Prior art date
Application number
BE8700787A
Other languages
English (en)
French (fr)
Inventor
Machida Minoru
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of BE1000253A3 publication Critical patent/BE1000253A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BE8700787A 1986-07-18 1987-07-15 Preparation pharmaceutique stable contenant un facteur de stimulation des colonies de granulocytes et procede pour la produire. BE1000253A3 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16948986 1986-07-18
JP16948786 1986-07-18
JP16948686 1986-07-18
JP16948886 1986-07-18

Publications (1)

Publication Number Publication Date
BE1000253A3 true BE1000253A3 (fr) 1988-09-27

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8700787A BE1000253A3 (fr) 1986-07-18 1987-07-15 Preparation pharmaceutique stable contenant un facteur de stimulation des colonies de granulocytes et procede pour la produire.

Country Status (24)

Country Link
KR (1) KR930004597B1 (de)
CN (1) CN1033738C (de)
AT (1) AT402259B (de)
AU (1) AU611856B2 (de)
BE (1) BE1000253A3 (de)
CA (1) CA1297007C (de)
CH (1) CH671157A5 (de)
DE (1) DE3723781C2 (de)
DK (1) DK171308B1 (de)
ES (1) ES2010226A6 (de)
FR (1) FR2601591B1 (de)
GB (1) GB2193631B (de)
GR (1) GR871067B (de)
HK (1) HK64893A (de)
HU (1) HU198627B (de)
IE (1) IE60290B1 (de)
IL (1) IL83220A (de)
IT (1) IT1218927B (de)
NL (1) NL192917C (de)
NO (1) NO171828C (de)
PT (1) PT85343B (de)
SE (1) SE503312C2 (de)
SG (1) SG64393G (de)
YU (1) YU47543B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NO179479C (no) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP2911496B2 (ja) 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
EP0459516A1 (de) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
EP0582932A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
WO1999044630A1 (en) * 1998-03-06 1999-09-10 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
AU6875900A (en) 1999-09-08 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
US7163671B2 (en) * 2000-02-29 2007-01-16 Chugai Seiyaku Kabushiki Kaisha Long-term stabilized formulations
EP1129720B1 (de) * 2000-02-29 2004-06-23 Pfizer Products Inc. Stabilisierter Granulozyten-Kolonie-stimulierender Faktor
EP2213743A1 (de) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albuminfusionsproteine
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
KR20030027077A (ko) * 2000-09-01 2003-04-03 쥬가이 세이야쿠 가부시키가이샤 장기 안정화 용액 제제
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
KR101235507B1 (ko) 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
WO2008075371A2 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
PT2525787T (pt) 2010-01-19 2017-12-18 Hanmi Science Co Ltd Formulações líquidas para conjugado de g-csf de longa ação
EP2399572A1 (de) 2010-06-22 2011-12-28 Sandoz AG Langzeitaufbewahrung von nicht-glykosyliertem rekombinantem humanem G-CSF
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
CN112512480B (zh) * 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016477A (en) * 1978-03-20 1979-09-26 Green Cross Corp HGI-glycoprotein and isolation thereof
EP0098110A2 (de) * 1982-06-24 1984-01-11 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Zusammensetzung mit längerer Wirkung
EP0162332A1 (de) * 1984-04-26 1985-11-27 Suntory Limited Zubereitung mit Gehalt an stabilisiertes Polypeptid mit Gamma-Interferon Aktivität
EP0178576A1 (de) * 1984-10-09 1986-04-23 Chugai Seiyaku Kabushiki Kaisha Verfahren und Zusammensetzung zur Vermeidung der Adsorption eines Arzneimittels

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JP2512453B2 (ja) * 1985-02-05 1996-07-03 シ−タス コ−ポレ−シヨン 天然のコロニ−促進因子―１の精製
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016477A (en) * 1978-03-20 1979-09-26 Green Cross Corp HGI-glycoprotein and isolation thereof
EP0098110A2 (de) * 1982-06-24 1984-01-11 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Zusammensetzung mit längerer Wirkung
EP0162332A1 (de) * 1984-04-26 1985-11-27 Suntory Limited Zubereitung mit Gehalt an stabilisiertes Polypeptid mit Gamma-Interferon Aktivität
EP0178576A1 (de) * 1984-10-09 1986-04-23 Chugai Seiyaku Kabushiki Kaisha Verfahren und Zusammensetzung zur Vermeidung der Adsorption eines Arzneimittels

Also Published As

Publication number Publication date
KR930004597B1 (ko) 1993-06-01
YU47543B (sh) 1995-10-03
IE60290B1 (en) 1994-06-29
CN87104963A (zh) 1988-02-24
DK368387D0 (da) 1987-07-15
YU134287A (en) 1989-06-30
KR880001297A (ko) 1988-04-22
DK171308B1 (da) 1996-09-02
IL83220A0 (en) 1987-12-31
GB8716904D0 (en) 1987-08-26
CN1033738C (zh) 1997-01-08
NL8701640A (nl) 1988-02-16
NO872966D0 (no) 1987-07-16
GR871067B (en) 1987-11-19
PT85343B (pt) 1990-04-30
PT85343A (en) 1987-08-01
AT402259B (de) 1997-03-25
ES2010226A6 (es) 1989-11-01
HK64893A (en) 1993-07-16
IT8767594A0 (it) 1987-07-10
HU198627B (en) 1989-11-28
IT1218927B (it) 1990-04-24
DE3723781C2 (de) 1999-09-02
CA1297007C (en) 1992-03-10
SG64393G (en) 1993-08-06
NO171828B (no) 1993-02-01
FR2601591A1 (fr) 1988-01-22
IL83220A (en) 1993-01-31
NO171828C (no) 1993-05-12
GB2193631B (en) 1990-11-21
AU611856B2 (en) 1991-06-27
SE8702907D0 (sv) 1987-07-17
IE871933L (en) 1988-01-18
AU7566587A (en) 1988-01-21
HUT44941A (en) 1988-05-30
NL192917B (nl) 1998-01-05
SE8702907L (sv) 1988-01-19
SE503312C2 (sv) 1996-05-13
NL192917C (nl) 1998-05-07
CH671157A5 (de) 1989-08-15
DK368387A (da) 1988-01-19
GB2193631A (en) 1988-02-17
DE3723781A1 (de) 1988-01-21
FR2601591B1 (fr) 1991-04-26
ATA177587A (de) 1996-08-15
NO872966L (no) 1988-01-19

Similar Documents

Publication Publication Date Title
BE1000253A3 (fr) Preparation pharmaceutique stable contenant un facteur de stimulation des colonies de granulocytes et procede pour la produire.
JP7150804B2 (ja) プラミノーゲンを含む医薬組成物及びその使用
US5919443A (en) Stable lyophilized pharmaceutical preparations of G-CSF
JP3530300B2 (ja) 安定なトランスグルタミナーゼ製剤およびそれらを製造する方法
JPH0552808B2 (de)
JPWO2001064241A1 (ja) 長期安定化製剤
FR2853547A1 (fr) Compositions pharmaceutiques injectables contenant de la piperacilline et du tazobactame, et procede pour leur production
AU738413B2 (en) Human growth hormone-containing aqueous pharmaceutical composition
FR2591485A1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
EP1060746A1 (de) Protein-freie präparationen
KR100807650B1 (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물의 동결 건조 제제 및 그 제조 방법
JPS63146826A (ja) 安定な顆粒球コロニ−刺激因子含有製剤
NZ234341A (en) Pharmaceutical surfactant suspensions for treatment of respiratory diseases
HU218103B (hu) Nem-glikozilezett, rekombináns humán interleukin-2 redukált alakját tartalmazó, stabilizált gyógyászati készítmény és eljárás előállítására
JPS63146827A (ja) 安定な顆粒球コロニ−刺激因子含有製剤
WO2023233277A1 (en) Lyophilized pharmaceutical compositions of copper histidinate
JPH07291865A (ja) プロスタグランジンｅ▲１▼の安定化組成物
JPWO2002017957A1 (ja) 長期安定化溶液製剤
UA50811C2 (uk) Ліофілізована композиція морфогенетичного фактора кістки, спосіб одержання ліофілізованої композиції морфогенетичного фактора кістки
JPH06166624A (ja) 血液保存剤および血液保存方法

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *CHUGAI SEIYAKU K.K.

Effective date: 20070715